CannTrust Holdings Inc (TSE:TRST) (OTCMKTS:OCTFF) (FRAC95) COO Brad Rogers stops by to discuss incredible Q2 earnings and reaching a 45,000 patient base. CannTrust is the second-most funded to capacity producer going into recreational markets on October 17 with 50,000 kilograms. Rogers explains that CannTrust has raised $100 million to finish an additional 600,000 square foot facility in the Niagara region. CannTrust has developed a zero-profile THC beverage, a potential “phenomenal base material for any other beverage in the market.”  Rogers mentions CannTrust will accelerate its partnership with Apotex as part its international development plan.

James West:   Welcome back to Midas Letter Live, everybody! Guess who’s here? Brad Rogers, Chief Operating Officer and President of CannTrust Holdings Inc., TSX TRST. I will point out, before we cut to Brad, one of the few up-performers on the market today. Brad, welcome back.

Brad Rogers:  Thank you, thank you for having me. Great day to have me back.

CannaInvestor Magazine Editor-in-Chief Louis Kyron joins James West in the Midas Letter studio to talk about the Canadian Medical Association’s recent declaration that it expects “the existing medical use framework to be dismantled, phased out, once legalization stats on October 17.” The pair address the impact on patients transitioning from medical teams, licensed producers, and special strains, to relying on retailers for information and guidance. Kyron discusses the growing body of research supporting cannabis as an alternative treatment to opiates. They examine cannabis taxation and what that means for the black market. The segment concludes with a discussion of cannabis brewing companies to watch.

James West:   Hey, welcome back to Midas Letter Live. My guest in this segment is Louis Kyron; he is the Editor-in-Chief of CannaInvestor Magazine, which you can find online at cannainvestormag.ca. Louis, thanks for joining me today.

Louis Kyron:  Thank you, James. Pleasure to be here.

James West:   Yeah, so Louis, there’s some issues with the whole idea of the entire Federal medical regime that you seem to believe represent some level of risk to patients and/or, I guess, by extension, investors. Can you give me a bit of an explanation of what you’re sort of fishing for there?

Louis Kyron:  Certainly, James. There’s a whole bunch of, obviously, smaller challenges that we read about, whether it’s the taxes being on medical cannabis, lack of benefits coverage, the black market threat, availability, and we can go on and on. I would say recently, the Canadian Medical Association has come out and declared – it’s on their website as well – that they expect the existing medical use framework to be dismantled, phased out, once legalization starts on October 17th.

I just don’t see, from a patient point of view, how patients are expected to transition from their medical team and licensed producers to get special strains, especially high CBD, for example, to a dispensary network, you know, relying on retailers, if you will, for that same information.

From an investor perspective of course, is we’ve all been led to believe the markup, the margins, to be more on the medical side, and there’s a bit more branding there as well. I mean, strains and so forth. And what would happen to those strains and all of that if it’s strictly recreational?

So I see a number of concerns, and you know, tho

Heritage Cannabis Holdings Corp (CNSX:CANN) (OTCMKTS:UMBBF) (FRA:2UE) Chairman Clint Sharples discusses the completion of Heritage’s buildout and licensing in Falkland, British Columbia under subsidiary PhyeinMed. Sharples addresses the need for indoor scalability to meet the needs of the Canadian retail market in 2019. Furthermore, he explains Heritage’s potential acquisition of CannaCure, a Niagara-based company with a 122,000 square foot greenhouse facility. The pair discuss Heritage’s CapEx requirements to meet Phase 2 plans for PhyeinMed and CannaCure.

James West:   Hey, welcome back to Midas Letter Live! In this segment, my guest is Clint Sharples, and he’s the Chairman of Heritage Cannabis Holdings Corp., trading on the CSE under the symbol CANN. Welcome back, Clint.

Clint Sharples:    Thank you. Nice to be back here again.

Tilray Inc (NASDAQ:TLRY) (FRA:2HQ) CEO Brendan Kennedy discusses Tilray’s path toward becoming the first cannabis company to IPO on the US Exchange. Kennedy outlines Tilray’s current global footprint, highlighting the company’s expected growth on the cultivation side from 8 to 90 metric tons by the end of the year. The key to Tilray’s international growth is its facility in Portugal, which allows for both indoor and outdoor growing, and tariff-free access to European Union markets. Kennedy explains that the rapid increase in countries legalizing medical cannabis combined with Canada’s leading role in shifting recreational cannabis laws will result in changes to US law in the next 3 to 4 years.

James West:  Hey! Welcome back to Midas Letter Live. My guest this segment is Brendan Kennedy, CEO of Tilray. In trading on NASDAQ under the symbol TLRY. Brandon thank you for joining me again.

Brendan Kennedy: Thank you for having me.

James West: So, amazing transformat

Emerald Health Therapeutics (CVE:EMH) (OTCMKTS:EMHTF) (FRA:TBD) CEO Chris Wagner discusses their recent deal to be part of the British Columbia retail market. Wagner explains that Emerald Health, the province’s largest cannabis producer, was recently licensed to sell out of its one million square foot facility in Delta, British Columbia. The pair talk about Emerald Health’s deal to acquire Northern Vine Canada, a licensed dealer, which allows Emerald Health to develop new, innovative products as part of its development push. Emerald’s “objective is to have multi-billion-dollar products that are patented, that we will sell all over the world” in medical markets such as Australia and Germany.

James West:   Hey, welcome back to Midas Letter Live. My guest in this segment is Chris Wagner; he’s the CEO of Emerald Health Therapeutics, trading on the Venture under the symbol EMH. Chris, thanks for joining me today.

Chris Wagner: Thanks, James. Good to be here.

Hempco Food and Fiber Inc (CVE:HEMP) (OTCMKTS:HMPPF) (FRA:22Y) CEO Diane Jang discusses the company’s range of available hemp-based consumer products and the future applications of hemp CBD.  As of October 17, the Cannabis Act will allow companies to extract and commercialize non-narcotic CBD’s from hemp flowers, leaves and chaff, which were previously all discarded. Aurora Cannabis Inc (TSE:ACB) (OTCMKTS:ACBFF) (FRA:21P) have a 52.5 percent share majority ownership in the company and Hempco will act as their mainstream food play. Hempco plan to capture market share of the growing, Infinium Global Research predicted 2.2 US billion dollar, hemp-based food industry.

James West:     Welcome back to Midas Letter Live. It’s Friday. And my guest right now is Diane Jane. She’s the CEO of Hempco Food and Fibre Inc trading on the TSX-V under the symbol H E M P. Diane welcome to the show.

Diane Jane:     Thank you James.

Alcanna Inc (TSE:CLIQ) (OTCMKTS:LQSIF) CEO James Burns discusses the company’s massive North American profile – being the largest private retailer of liquor in Canada. Alcanna are 25% owned by Aurora Cannabis Inc (TSE:ACB) (OTCMKTS:ACBFF) (FRA:21P), with the option to increase to 40 percent ownership through the exercise of warrants. Alcanna provides Aurora with a proven retail strategy using their long history and established distribution channels in liquor and adult consumable products. Burns also discusses opening retail cannabis stores under the “Aurora” brand name across Canada and the future opportunity Ontario provides both companies.

James West:    Hey, welcome back to Midas Letter Live. My guest in this segment is James Burns. He is the CEO of Alcanna Inc., trading on the TSX under the symbol CILQ. James, welcome.

James Burns:   Thank you.

Aurora Cannabis Inc (TSE:ACB) (OTCMKTS:ACBFF) (FRA:21P) CCO Cam Battley and Editorial Director of Cannabis Business Times and Cannabis Dispensary magazines Noelle Skodzinski joins James West for the first episode of Cannabis Corner. Results are announced for Micron Waste Technologies (CNSX:MWM) (OTCMKTS:MICWF) (FRA:7FM2) waste digestor naming contest. De-prohibition in the United States, Aurora’s Australis Capital Inc deal, and cannabis waste processes are all discussed.

James West:  Hey! Welcome to Midas Letter Live. In this segment we’re doing something brand new. We’re having a talk show style discussion. My first guest ever in this format are Cam Battley, Chief Corporate Officer from Aurora Cannabis Inc and our special guest is Noelle Skodzinski and she is the corporate; sorry what was the title again?

Noelle Skodzinski:  Editorial director.

James West:  Editorial director of Cannabis Business Times and Cannabis Dispensary. Hold those up. These are the magazines that are taking the United States by storm and we’re going to see them here soon too aren’t we?

Cam Ba

Aurora Cannabis Inc (TSX:ACB) (OTCQB:ACBFF) (FRA:21P) CCO Cam Battley has nothing but praise for Canopy Growth Corp (TSE:WEED) (NYSE:CGC) (FRA:11L1) CEO Bruce Linton and the recent combination (effectively) of Constellation Brands (NYSE:STZ)and Canopy. But he also suggests that, just as it always has been, Aurora will be close on Canopy’s heels with its own value catalysts.

Transcript:

James West:    Cam Battley. What are you doing here?

Cam Battley:   James West. Hi.

James West:    You know, it’s so funny that you’re here right now.

Cam Battley:   Tell me, why is it so funny?

James West:    I just bought $10,000 worth of your stock. Do you know why I just upped my position by another $10,000?

Cam Battley:   Please, tell me.

James West:    Because you reminded me that I’m actually going to get a share and a warrant of Australis if I’m a shareholder of record on the date of record that is not yet announced, but you’re comfortable in telling me that.

Cam Battley:   Subject to the ratio that we have yet to determine and will announce, but yes.

James West:    Anyways, there’s a gift there.

Cam Battley:   There is a gift. It really, truly is a gift; it’s a gift to our shareholders, and we’re giving them something of significant value that we hope to turn into an awful lot more value in a very short period of time.

James West:    Righ

Canopy Growth Corp (TSE:WEED) (NYSE:CGC) (FRA:11L1) was the recipient of what was effectively a $5 billion takeover by NYSE-listed Constellation Brands (NYSE:STZ). Bruce Linton, CEO and Chairman of the Board of Canopy explains how he first got the attention of Constellation CEO Robert Sands that led to the historic partnership.

Transcript:

James West:    Hey, welcome back to Midas Letter Live. My guest in this segment probably doesn’t need much introduction. Oh, we’ll give him an introduction – Mr. $5 Billion Man himself, Bruce Linton, CEO and founder of [drums] Canopy Growth Corporation.

Bruce Linton:  Wow, man, I thought maybe you got the 5 billion. Got the new studio…

James West:    I feel like I did.

Bruce Linton:  You know, I come in, the signage is upgraded…

James West:    It’s a proximity thing.

Bruce Linton:  It’s good, I like it.

James West:    It is, it is.

Bruce Linton:  Fancy microphones.

James West:    Yeah. We’re making movies now. [laughter]

Bruce Linton:  Wow. You’re presenting your business plan, which was, “I’m going to get a lot of content and I’m going to spend a lot of money doing it, and then I don’t know what happens next,”, you seem to have made an evolution off of that.

James West:    Right. Well, actually, you didn’t read to the end of the business plan.

Bruce Linton:  Do you remember that in my lobby?

James West:    Yeah.

Bruce Linton:  So this is a good business plan, except it’s missing the business part. It’s more like a content part.

James West:    I actually did write this business plan back in 2012, and we are execu